1367553-87-4

Upstream product

• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 117460-96-5 methyl (2S,4R)-4-((tert-butyldimethylsilyl)oxy)pyrrolidine-2-carboxylate 
• 1367552-60-0 (R)-methyl 3-((tert-butyldimethylsilyl)oxy)-3,4-dihydro-2H-pyrrole-5-carboxylate 
• 1367552-62-2 1-benzyl 2-methyl (R)-4-((tert-butyldimethylsilyl)oxy)-4.5-dihydro-1H-pyrrole-1,2-dicarboxylate 
• 1367552-64-4 (2R,3S,4R)-1-benzyl 2-methyl 4-((tert-butyldimethylsilyl)oxy)-3-methylpyrrolidine-1,2-dicarboxylate 
• 1367552-66-6 C₁₃H₂₇NO₃Si 
• 1367552-68-8 C₁₃H₂₅NO₃Si 
• 1392481-18-3 C₁₂H₂₁NO₅ 
• 1367552-70-2 (2S,3S,4R)-1-boc-4-hydroxy-3-methylproline 
• 1283180-95-9 2-(2-chloro-1-isopropyl-1H-benzo[d]imidazol-4-yl)-4-cyclohexylthiazole 
• 1367552-73-5 C₇H₁₃NO₃ 
• 1392481-48-9 C₁₂H₂₄ClNO₃Si 

Relevant academic research and scientific papers

SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formulae I, la, II,IIa,III, IIIa, Illb, IV, IVa, IVb, V, Va, Vb, VI, VIa, VIb, and VIc, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. The embodiments also provide methods for the synthesis of subject compounds and intermediates in the synthetic methods.